CD38 and plasma cell myeloma: The efficacy of the anti-CD38 monoclonal antibody in delaying progression to multiple myeloma was assessed in high-risk MGUS or low-risk SMM patients in the phase 2 study, D-PRISM (Precision Intervention Smoldering Myeloma, NCT03236428).